SeaStar Medical Announces Significant Cost Savings and Improved Survival Rates with QUELIMMUNE Therapy for Pediatric AKI in Newly Published Study
SeaStar Medical Holding Corporation has published a health economic study on its QUELIMMUNE therapy for pediatric Acute Kidney Injury (AKI). The study reveals an estimated 18% reduction in hospitalization costs, translating to savings of $69,146 per hospitalization compared to standard treatments. The therapy also boasts a 77% survival rate in treated patients. QUELIMMUNE, approved by the FDA in 2024, is aimed at pediatric patients with AKI due to sepsis. SeaStar is conducting further trials to assess the therapy's safety and efficacy.
SeaStar Medical Holding Corporation has announced the results of a recently published health economic study concerning the QUELIMMUNE therapy, aimed at treating pediatric Acute Kidney Injury (AKI). The study, published in the Journal of Medical Economics, indicates significant cost savings, estimating a reduction of approximately 18% per hospitalization. The economic analysis projects a cost savings of $69,146 per hospitalization when QUELIMMUNE is used, compared to standard treatments. This potential cost reduction is attributed to shorter hospital stays and increased survival rates, as clinical data shows a 77% survival rate in patients treated with QUELIMMUNE. The therapy, approved by the FDA under a Humanitarian Device Exemption in 2024, is designed for pediatric patients with AKI due to sepsis or septic conditions. SeaStar Medical is also conducting the NEUTRALIZE-AKI pivotal trial to further assess the safety and efficacy of its SCD therapy in ICU patients with AKI. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seastar Medical Holding Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9521251-en) on September 02, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
